LLY Jan 2025 400.000 put
| Previous close | 2.2500 |
| Open | 2.6000 |
| Bid | 2.1000 |
| Ask | 2.6000 |
| Strike | 400.00 |
| Expiry date | 2025-01-17 |
| Day's range | 2.6000 - 2.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.77k |
- Reuters
India's Biocon developing its own version of Wegovy, clinical trial likely next year
Indian drugmaker Biocon , looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.
Investor's Business DailyIs Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?
Lilly is soon planning to ask global regulators to approve tirzepatide for sleep apnea treatment. Is Eli Lilly stock a buy?
Investor's Business DailyHow The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.
